Imugene announced termination of its supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA. Imugene is continuing with its clinical trial to evaluate the safety and efficacy with the use of Imugene's HER-Vaxx, a B-cell activating immunotherapy in patients with HER-2 positive gastric cancer in combination with anti-PD-1 therapy.